Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain

The overall survival of patients who received genomically matched therapy was not significantly longer than that of patients receiving treatment only other than genomically matched therapy in the breast invasive ductal carcinoma (A), colorectal adenocarcinoma (B), and pancreatic adenocarcinoma (C) c...

Descripción completa

Detalles Bibliográficos
Autor principal: Ikegami, Masachika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
LETTERS TO THE EDITOR
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323084/
https://www.ncbi.nlm.nih.gov/pubmed/37121885
http://dx.doi.org/10.1111/cas.15826
Descripción
Sumario:The overall survival of patients who received genomically matched therapy was not significantly longer than that of patients receiving treatment only other than genomically matched therapy in the breast invasive ductal carcinoma (A), colorectal adenocarcinoma (B), and pancreatic adenocarcinoma (C) cohorts.[Image: see text]

Ejemplares similares